Skip to content
Homepage
Author:
Sironax USA, Inc.
Posted Date:
May 20, 2026
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
Sironax USA, Inc.
May 20, 2026
Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting
Sironax USA, Inc.
April 22, 2026
Sironax Appoints Clive Wang to Board of Directors
Sironax USA, Inc.
March 26, 2026
Sironax Announces Upcoming Poster Presentation on NAMPT Activation
Sironax USA, Inc.
March 20, 2026
